Jul. 12, 2018—A drug used to treat diabetes may point to new therapies for respiratory syncytial virus (RSV) bronchiolitis — inflammation and obstruction of the lungs’ small airways. A multi-disciplinary team of Vanderbilt investigators has demonstrated that liraglutide reduces the inflammatory response to RSV infection in a mouse model of the disease.
Mar. 1, 2018—Infants who have higher amounts of the bacterium Lactobacillus present in their nose or upper part of the throat during an acute respiratory syncytial virus (RSV) infection are less likely to develop childhood wheezing later in life, a new Vanderbilt-led Center for Asthma Research study found.
Feb. 9, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.
Oct. 20, 2016—Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.
Jul. 21, 2016—Investigators in the Division of Allergy, Pulmonary and Critical Care Medicine recently received a $4.5 million Asthma and Allergic Diseases Cooperative Research Center (AADCRC) grant from the National Institutes of Allergy and Infectious Diseases (NIAID).
Feb. 26, 2015—Respiratory viruses, not bacterial infections, are the most commonly detected causes of community-acquired pneumonia in children, according to new research released Feb. 26 in the New England Journal of Medicine.
Jul. 17, 2014—New Vanderbilt-led research published in the Journal of Infectious Diseases has identified an antibody that shows promise in preventing and treating human metapneumovirus (MPV) and respiratory syncytial virus (RSV) — the two leading causes of respiratory infections in young children.
Feb. 5, 2014—Vanderbilt University scientists have contributed to a major finding, reported this week in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.